Company Listing
Proteon Therapeutics

Proteon is developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company’s lead product, a recombinant human elastase, is in late-stage trials to prolong the patency and reduce the failure of haemodialysis vascular access in patients with chronic kidney disease. The company went public in October 2014.

BACK
Location
Waltham, Massachusetts
CEO
Timothy Noyes
Abingworth Partner
Tim Haines
Website Address

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Company Listing

Proteon is developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company’s lead product, a recombinant human elastase, is in late-stage trials to prolong the patency and reduce the failure of haemodialysis vascular access in patients with chronic kidney disease. The company went public in October 2014.

Location
Waltham, Massachusetts
CEO
Timothy Noyes
Abingworth Partner
Tim Haines
Website Address
BACK
 
Copyright Abingworth 2017